NCT00560053已完成3 期
Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Response
PETHEMA Foundation0 个研究点目标入组 500 人开始时间: 2000年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
简要总结
The study objectives are to investigate the toxicity and the BUMEL response rate; in patients who reach the CR after autotransplantation, investigate if negativization of IF, influences in disease evolution; in patients in PR after autotransplantation, analyze if the second intensive procedure is capable of increasing the response rate and increasing the survival so that patients who reached the CR with the first transplantation; Patients with MM primarily resistant to the chemotherapy, investigate the efficacy of a double transplantation; patients submitted to double transplantation, control the efficacy of the second transplantation in front of allogenic transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 69 Years(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Less 70 years
- •Symptomatic MM (pain, anemia, infection, haemorrhage, loss of weight, hypercalcemia, extramedulary plasmocytoma, creatinine >2 mg/dl).
- •No previous chemotherapy
排除标准
- •>70 years
- •myeloma quiescent
- •cardiopathy
- •liver disfunction
- •Hepatitis B-C +
- •Previous chemotherapy
研究者
相似试验
进行中(未招募)
不适用
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)Multiple MyelomaNCT01838512Bristol-Myers Squibb2,555
终止
1 期
A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple MyelomaMultiple MyelomaNCT00039754Poniard Pharmaceuticals
已完成
2 期
A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory ArthritisPsoriatic ArthritisNCT02969525UCB Biopharma S.P.R.L.206
终止
1 期
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell LymphomaMultiple Myeloma, RefractoryDiffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma RefractoryMultiple Myeloma in RelapseNCT05121103Epizyme, Inc.13
Unknown
不适用
MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) SurveySmoldering Multiple MyelomaCoronavirusMultiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceNCT04727294HealthTree Foundation1,500
